To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Self-expandable metallic stent
A self-expandable metallic stent (or SEMS) is a metallic tube, or stent, used in order to hold open a structure in the gastrointestinal tract in order to allow the passage of food, chyme, stool, or other secretions required for digestion. SEMS are inserted by endoscopy, wherein a fibre optic camera is inserted either through the mouth or retrograde through the colon, in order to reach an area of narrowing. As such, it is termed an endoprosthesis. SEMS can also be inserted using fluoroscopy where an X-ray image is used to guide insertion, or used as an adjunct to endoscopy.
The vast majority of SEMS are used to alleviate symptoms caused by cancers of the gastrointestinal tract that obstruct the interior of the tube-like (or luminal) structures of the bowel — namely the esophagus, duodenum, common bile duct and colon. SEMS are designed to be permanent and, as a result, are often used when the cancer is at an advanced stage and cannot be removed by surgery.
Additional recommended knowledge
Composition and structure
Self-expandable metallic stents are cylindrical in shape, and are devised in a number of diameters and lengths to suit the application in question. They typically consist of cross-hatched, braided or interconnecting rows of metal that are assembled into a tube-like structure. SEMS, when unexpanded, are small enough to fit through the channel of an endoscope, which is meant for delivery of devices for therapeutic endoscopy. They expand through a deployment device which is placed at the end of the SEMS, and are held in place against the wall of the luminal surface by friction.
SEMS may be coated with chemicals designed to prevent tumour ingrowth; these are termed "covered" stents. Nitinol (a shape memory nickel-titanium alloy), polyurethane, and polyethylene are typically used as coatings for SEMS. Covered stents carry the advantage of preventing tumours from growing into the stent, although they run the risk of increased migration after deployment.
A plastic self-expanding stent (Polyflex, Boston Scientific) has also been developed for similar applications. It confers an additional advantage as it is designed to be removable, and may have a less traumatic insertion than metal stents. The Polyflex stent has shown benefit in palliation of esophageal malignancies.
The primary application of SEMS is in the palliation of tumours that obstruct the gastrointestinal tract. When they expand within the lumen, they are able to hold open the structure and allow passage of material, such as food, stool, or other secretions. The usual applications are for cancers of the esophagus, pancreas, bile ducts and colon that are not amenable to surgical therapy. SEMS may be used to treat additional complications of cancer, such as tracheoesophageal fistulas that may result from esophageal cancer, and gastric outlet obstruction which may result from stomach, duodenal or pancreatic cancer.
SEMS and self-expanding plastic stents have also been used for non-malignant conditions that cause narrowing or leaks of the esophagus or colon. These include peptic strictures caused by esophageal reflux and perforations of the esophagus. SEMS may also be placed in tandem fashion to treat ingrowth or overgrowth tumours, and fractures or migration of other SEMS. For the latter, the second SEMS in usually deployed within the lumen of the first.
SEMS are also sometimes used in the vascular system, usually in the aorta and peripheral vascular system. In the past they have been used for saphenous vein graft and native coronary artery percutaneous coronary interventions.
Self-expandable metallic stents are typically inserted at the time of endoscopy, usually with assistance with fluoroscopy or x-ray images taken to guide placement. Prior to the development of SEMS small enough to pass through the channel of the endoscopy, SEMS were deployed using fluoroscopy alone.
Esophageal SEMS are placed after a gastroscopy is performed to identify the area of narrowing. The area may need to be dilated in order to allow the gastroscope to pass. The tumour is usually better seen with the direct vision of endoscopy than on a fluoroscopic image. As a result, radio-opaque markers are usually placed on the surface of the patient in order to mark the area of narrowing on fluoroscopy. The SEMS is placed through the channel of the endoscope into the esophagus over a guidewire, marked on fluoroscopy, and mechanically deployed (using a device that sits outside of the endoscope) such that it expands when in position. Hypaque or other water-soluble dye may be placed through the passage to ensure patency of the stent on fluoroscopy. Enteric and colonic SEMS are inserted in a similar fashion, but in the duodenum and colon respectively.
Biliary SEMS are used to palliatively treat tumours of the pancreas or bile duct that obstruct the common bile duct. They are inserted at the time of ERCP, a procedure that uses endoscopy and fluoroscopy to access the common bile duct. The bile duct is cannulated with the assistance of a guidewire and the sphincter of Oddi that is located at its base is typically cut. A wire is kept in the bile duct, and the SEMS is deployed over the wire in a similar fashion as esophageal stents. The location of the SEMS is confirmed by fluoroscopy.
The complications of SEMS are related to a number of factors. The first is that the endoscopic procedure used to insert a SEMS involves the use of sedative medications, which may lead to oversedation, aspiration, or drug reaction. SEMS also expand and can lead to perforation of the bowel or compression of structures adjacent to the bowel.
Long-term complications of SEMS may be related to the underlying tumour being treated: the tumour may grow into the stent wall (tumour ingrowth) or over the end of the stent (tumour overgrowth), leading to obstruction. These complications may be limited by the use of coated stents. Tumour ingrowth or overgrowth can be additionally palliated by the placement of a second stent through the lumen of the first, through electrocautery or argon plasma coagulation of the tumour tissue in the stent, or through the use of photodynamic therapy.
Over time, SEMS may also migrate to a different position that does not help with treatment of the obstructed area. This may be treated with placement of a second SEMS, or endoscopic attempts to reposition or remove the first. Rarely, SEMS may fracture or intussescept after endoscopic intervention.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Self-expandable_metallic_stent". A list of authors is available in Wikipedia.|